当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.

Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.

Abstract：

BACKGROUND:Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1-6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected with HCV GT1a, 1b, 2, 3 and 4, VOX was well-tolerated and resulted in maximal mean viral load reduction >3 log10 IU/ml at the 100 mg dose across all genotypes evaluated. This report characterizes the HCV NS3 RAS in the study. METHODS:The NS3 gene was amplified and successfully deep sequenced using MiSeq for 66 patients at baseline and 61 patients post-baseline using 15% and 1% assay cutoffs. RESULTS:With a 15% assay cutoff, pretreatment HCV NS3 RAS were present in the HCV of 38% (9/24) of patients with GT1a and 5% (1/19) with GT3a; there were no pretreatment NS3 RAS present in patients with GT1b (n=6), GT2 (n=7) or GT4 (n=4). In patients with and without pretreatment NS3 RAS, ≥3.4 log10 mean maximal viral load reductions over 3 days of VOX administration were observed. The majority of patients did not have detectable treatment-emergent NS3 RAS and only 12% (7/53) and 26% (14/53) had emergent NS3 RAS using 15% and 1% cutoffs, respectively. No NS3 RAS were detected in patients with GT2 or GT4. A156T or A156V were the most prevalent emergent NS3 RAS in patients with GT1a or GT1b infection, but were not observed in patients with GT3 infection. CONCLUSIONS:The lack of selection of NS3 RAS in the majority of patients demonstrates a high resistance barrier for VOX. ClinicalTrails.gov identifier NCT02185794.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Lawitz E,Yang JC,Stamm LM,Taylor JG,Cheng G,Brainard DM,Miller MD,Mo H,Dvory-Sobol H

doi

10.3851/IMP3202

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

325-334

issue

4

eissn

1359-6535

issn

2040-2058

journal_volume

23

pub_type

临床试验,杂志文章,多中心研究,随机对照试验

相关文献

ANTIVIRAL THERAPY文献大全
  • MicroRNAs: role and therapeutic targets in viral hepatitis.

    abstract：:MicroRNAs regulate gene expression by binding to the 3'-untranslated region (UTR) of target messenger RNAs (mRNAs). The importance of microRNAs has been shown for several liver diseases, for example, viral hepatitis. MicroRNA-122 is highly abundant in the liver and is involved in the regulation of lipid metabolism. Mi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2766

    authors： van der Ree MH,de Bruijne J,Kootstra NA,Jansen PL,Reesink HW

    更新日期：2014-01-01 00:00:00

  • Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.

    abstract：OBJECTIVE:The lipodystrophy syndrome is a major adverse effect of highly active antiretroviral therapy (HAART), associated with altered circulating levels and adipose tissue mRNA expression of proinflammatory cytokines interleukin-6 (IL-6) and tumour necrosis factor (TNF)alpha, and adiponectin. Proinflammatory cytokine...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Lagathu C,Bastard JP,Auclair M,Maachi M,Kornprobst M,Capeau J,Caron M

    更新日期：2004-12-01 00:00:00

  • Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study.

    abstract：OBJECTIVE:To assess the impact of nucleoside analogue reverse transcriptase inhibitor (NRTI) combination therapy on muscle and liver lactate metabolism in HIV-infected patients. METHODS:This cross-sectional study involved HIV-infected patients who were either antiretroviral-naive (Group 1) or were receiving either a s...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Ghosn J,Guiguet M,Jardel C,Benyaou R,Zeller V,Simon A,Valantin MA,Amellal B,Assoumo L,Hogrel JY,Costagliola D,Katlama C,Lombès A

    更新日期：2005-01-01 00:00:00

  • Maternal antiretroviral prophylaxis and breastfeeding.

    abstract：:The prevention of mother-to-child transmission of HIV-1 during breastfeeding is a major concern in resource-poor settings where alternatives to breast milk may be unaffordable, unsafe and limited by social stigma. The use of triple-drug antiretroviral regimens initiated during pregnancy and continued throughout breast...

    journal_title：Antiviral therapy

    pub_type： 评论,杂志文章

    doi：10.3851/IMP2314

    authors： Marzolini C,Gray GE

    更新日期：2012-01-01 00:00:00

  • Antiviral activity of FNC, 2'-deoxy-2'-β-fluoro-4'-azidocytidine, against human and duck HBV replication.

    abstract：BACKGROUND:New drugs are needed to combat HBV infection. We investigated the anti-HBV activity of the deoxycytidine analogue FNC, which has anticancer activity and has been found to inhibit HCV replication. METHODS:In this study, a human hepatoma HepG2.2.15 cell culture system and duck HBV (DHBV) infection model were ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2094

    authors： Zheng L,Wang Q,Yang X,Guo X,Chen L,Tao L,Dong L,Li Y,An H,Yu X,Wang Q,Chang J

    更新日期：2012-01-01 00:00:00

  • External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

    abstract：OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Hammond E,Almeida CA,Mamotte C,Nolan D,Phillips E,Schollaardt TA,Gill MJ,Angel JB,Neurath D,Li J,Giulivi T,McIntyre C,Koultchitski G,Wong B,Reis M,Rachlis A,Cole DE,Chew CB,Neifer S,Lalonde R,Roger M,Jeanneau A

    更新日期：2007-01-01 00:00:00

  • Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.

    abstract：BACKGROUND:Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. METHOD:Thirty-three ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Chang L,Ernst T,Witt MD,Ames N,Walot I,Jovicich J,DeSilva M,Trivedi N,Speck O,Miller EN

    更新日期：2003-02-01 00:00:00

  • Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.

    abstract：BACKGROUND:Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. METHODS:Linear mixed models were fitted to study changes in VL and potential associated...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP1489

    authors： European Collaborative Study.

    更新日期：2010-01-01 00:00:00

  • Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation.

    abstract：BACKGROUND:HDV infection is a cause of severe liver disease. Diagnosis and monitoring of HDV RNA are important to patient management. Since 2012, a WHO standard for HDV RNA quantification has been available; however, the impact of RNA extraction methods on HDV viral load quantification has never been evaluated. METHOD...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3281

    authors： Bremer B,Anastasiou OE,Ciesek S,Wedemeyer H

    更新日期：2019-01-01 00:00:00

  • Association between systemic inflammation and obstructive sleep apnea in men with or at risk for HIV infection.

    abstract：BACKGROUND:We sought to determine whether markers of systemic inflammation are associated with the presence of moderate/severe obstructive sleep apnea (OSA) and whether this association differs based on HIV and HIV treatment status. METHODS:HIV-uninfected men (HIV-; n=60), HIV-infected men receiving HAART (HIV+/HAART;...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP2745

    authors： Brigham EP,Patil SP,Jacobson LP,Margolick JB,Godfrey R,Johnson J,Johnson-Hill LM,Reynolds S,Schwartz AR,Smith PL,Brown TT

    更新日期：2014-01-01 00:00:00

  • Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.

    abstract：BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Dahari H,Shudo E,Cotler SJ,Layden TJ,Perelson AS

    更新日期：2009-01-01 00:00:00

  • Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.

    abstract：OBJECTIVES:To characterize 1-year virological response to antiretroviral therapy and its determinants by sex. METHODS:This is a population-based analysis of antiretroviral therapy naive HIV-positive adult men and women. Factors associated with sex and with plasma HIV RNA viral load suppression to below 500 copies/ml w...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： O'Connell JM,Braitstein P,Hogg RS,Yip B,Craib KJ,O'Shaughnessy MV,Montaner JS,Burdge DR

    更新日期：2003-12-01 00:00:00

  • HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.

    abstract：:Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2425

    authors： Calle Serrano B,Manns MP

    更新日期：2012-01-01 00:00:00

  • Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals.

    abstract：BACKGROUND:The increased risk for cardiovascular disease (CVD) in HIV is well established. Despite high prevalence of viral hepatitis coinfection with HIV, there are few studies on the risk of CVD amongst antiretroviral therapy (ART)-treated coinfected patients. METHODS:Ontario HIV Treatment Network Cohort Study parti...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2724

    authors： Gillis J,Smieja M,Cescon A,Rourke SB,Burchell AN,Cooper C,Raboud JM,OHTN Cohort Study Group.

    更新日期：2014-01-01 00:00:00

  • Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART.

    abstract：BACKGROUND:This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort. METHODS:We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3358

    authors： Bijker R,Kiertiburanakul S,Kumarasamy N,Pujari S,Sun LP,Ng OT,Lee MP,Choi JY,Nguyen KV,Chan YJ,Merati TP,Cuong DD,Ross J,Jiamsakul A,IeDEA Asia-Pacific.

    更新日期：2020-01-01 00:00:00

  • Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.

    abstract：BACKGROUND:A significant proportion of hepatitis C patients treated with unmodified interferon plus ribavirin fail to respond. The optimal therapy for these patients has not been established yet. The objective of this study was to assess the efficacy and safety of peginterferon plus ribavirin with or without amantidine...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Hasan F,Al-Khaldi J,Asker H,Al-Ajmi M,Owayed S,Varghese R,Siddique I,Al-Nakib B

    更新日期：2004-08-01 00:00:00

  • Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).

    abstract：BACKGROUND:Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses. METHODS:ACTG A5118 assessed the antiretroviral activity and safety of DAPD (300 mg orally, twice daily) v...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：

    authors： Gripshover BM,Ribaudo H,Santana J,Gerber JG,Campbell TB,Hogg E,Jarocki B,Hammer SM,Kuritzkes DR,A5118 Team.

    更新日期：2006-01-01 00:00:00

  • Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

    abstract：BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Verheyen J,Litau E,Sing T,Däumer M,Balduin M,Oette M,Fätkenheuer G,Rockstroh JK,Schuldenzucker U,Hoffmann D,Pfister H,Kaiser R

    更新日期：2006-01-01 00:00:00

  • Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.

    abstract：OBJECTIVES:To evaluate whether fuzzy operators can be usefully applied to the interpretation of genotypic HIV-1 drug resistance by experts, and to improve the prediction of salvage therapy outcome by adapting interpretation rules of genotypic resistance on the basis of their association with virological response data. ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： De Luca A,Vendittelli M,Baldini F,Di Giambenedetto S,Trotta MP,Cingolani A,Bacarelli A,Gori C,Perno CF,Antinori A,Ulivi G

    更新日期：2004-08-01 00:00:00

  • Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

    abstract：BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：10.3851/IMP2358

    authors： Vingerhoets J,Rimsky L,Van Eygen V,Nijs S,Vanveggel S,Boven K,Picchio G

    更新日期：2013-01-01 00:00:00

  • HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.

    abstract：BACKGROUND:HIV-1 shedding in genital secretions is associated with HIV transmission risk. Limited data exist on the effect of second-line lopinavir/ritonavir monotherapy (mLPV/r) on genital secretion of HIV RNA. METHODS:We measured HIV-1 in genital secretions of HIV-infected adults at time of failure from non-nucleosi...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：10.3851/IMP2737

    authors： Bunupuradah T,Bowonwattanuwong C,Jirajariyavej S,Munsakul W,Klinbuayaem V,Sophonphan J,Mahanontharit A,Hirschel B,Ruxrungtham K,Ananworanich J,HIV STAR Study team.

    更新日期：2014-01-01 00:00:00

  • The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.

    abstract：BACKGROUND:We examined the prevalence of ritonavir-boosted darunavir (DRV) resistance-associated mutations (RAMs) in HIV-infected children in the UK to determine the drug's potential clinical utility as a first-line or second-line protease inhibitor (PI). METHODS:The prevalence of DRV RAMs, identified from IAS 2010 an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2015

    authors： Donegan KL,Walker AS,Dunn D,Judd A,Pillay D,Menson E,Lyall H,Tudor-Williams G,Gibb DM,Collaborative HIV Paediatric Study.,UK HIV Drug Resistance Database.

    更新日期：2012-01-01 00:00:00

  • Lower limb high arterial flow induced by tenofovir and emtricitabine treatment.

    abstract：:Here, we describe a case of an HIV-infected patient with right lower limb oedema that appeared after initiation of tenofovir and emtricitabine treatment. The patient was fully investigated by serial heart and vessel echo-Doppler examination. Oedema of the lower limb was attributed to a transient drug-induced fivefold ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1302

    authors： Periard D,Yerly P,Hayoz D,Mazzolai L,Widmeier A,Cavassini M

    更新日期：2009-01-01 00:00:00

  • The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.

    abstract：BACKGROUND:Peripheral neuropathy (PN) in HIV-infected individuals is thought be due to a toxic effect on mitochondria induced by some nucleoside reverse transcriptase inhibitors (NRTI). METHODS:A time-to-event analysis was performed using data from the Delta trial to study the incidence of PN in HIV-infected individua...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：

    authors： Arenas-Pinto A,Bhaskaran K,Dunn D,Weller IV

    更新日期：2008-01-01 00:00:00

  • Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.

    abstract：BACKGROUND:Acute exacerbation (AE) in chronic hepatitis B (CHB) is usually followed by a spontaneous decline in HBV DNA levels. The subsequent treatment is controversial. In this study, we evaluated the efficacy and safety of pegylated interferon-α2a (PEG-IFN-α2a) for such CHB patients. METHODS:A total of 74 hepatitis...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2832

    authors： Cai Q,Chen F,Shao X,Zhang X,Zhao Z,Gao Z

    更新日期：2015-01-01 00:00:00

  • Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid.

    abstract：:Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in China, diagnostic methods have evolved. Despite definitive diagnoses, SFTS management has focused on prevention and supportive care. Although conservative treatment is effective for mild cases, there is an urgent need for an effective ther...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3036

    authors： Kim UJ,Kim DM,Ahn JH,Kang SJ,Jang HC,Park KH,Jung SI

    更新日期：2016-01-01 00:00:00

  • Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.

    abstract：BACKGROUND:This study aimed to examine the evolution of genotypic drug resistance prevalence in treatment-failing patients in the multicentre, Italian, Antiretroviral Resistance Cohort Analysis (ARCA). METHODS:Patients with a drug resistance genotype test performed between 1999 and 2006 at failure of a combination ant...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Di Giambenedetto S,Zazzi M,Corsi P,Gonnelli A,Di Pietro M,Giacometti A,Almi P,Trezzi M,Boeri E,Gianotti N,Menzo S,Del Gobbo R,Francisci D,Nerli A,Galli L,De Luca A,Antiretroviral Resistance Cohort Analysis Study Group.

    更新日期：2009-01-01 00:00:00

  • Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.

    abstract：BACKGROUND:Regulatory T-cells (Treg) hamper immune responses elicited by cancer vaccines. Therefore, depletion of Treg is being used to improve the outcome of vaccinations. METHODS:We studied whether an alphavirus vector-based immunotherapeutic vaccine changes the number and/or activity of Treg and if Treg depletion i...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1751

    authors： Walczak M,Regts J,van Oosterhout AJ,Boon L,Wilschut J,Nijman HW,Daemen T

    更新日期：2011-01-01 00:00:00

  • Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.

    abstract：BACKGROUND:Nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations (NAMs) can affect response to treatment with NRTIs and might also result in HIV-1 with reduced replication capacity. METHODS:A large commercial HIV-1 database (n=60,487) was analysed for the prevalence of NAMs, antiviral drug susceptibil...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： McColl DJ,Chappey C,Parkin NT,Miller MD

    更新日期：2008-01-01 00:00:00

  • Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial.

    abstract：BACKGROUND:Protease inhibitors (PI) have relatively low penetration into the genital tract, raising concerns about the potential for genital HIV RNA shedding in patients taking PI-based regimens, particularly PI monotherapy (PI-mono). METHODS:We measured HIV RNA and PI drug concentrations in samples of semen, cervico-...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3340

    authors： Arenas-Pinto A,Stöhr W,Khoo S,Clarke A,Beeching N,Warwick Z,Lee V,Else L,Wiggins R,Ferns B,Nastouli E,Dunn D,Lacey CJ,Paton NI,Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Genital Secretion sub-study T

    更新日期：2020-01-01 00:00:00